3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
4
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
6
Sarcoma
3
Pancreatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Colorectal Neoplasms
2
Whole-Brain Radiotherapy
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian Cancer Recurrent
1
Neoplasm Metastasis
1
Locally Advanced Thyroid Gland Carcinoma
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hyperthermia
1
HER2-Negative Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Craniopharyngioma
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
57
Carboplatin
34
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
Specimen Handling
15
130-nm albumin-bound paclitaxel
15
toripalimab
11
Drug Therapy
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
anlotinib
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled